Sona Nanotech Inc. (C:SONA)
Business Focus: Medical Equipment, Supplies & Distribution (NEC)
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| Company Contact | |
| Address: | Purdy's Wharf Tower 2 1969 Upper Water St Suite 2001 HALIFAX NS B3J 3R7 |
| Tel: | N/A |
| Website: | https://www.sonanano.com |
| IR: | See website |
| Key People | ||
| Darren Rowles President, Chief Scientific Officer | David Andrew Regan Chief Executive Officer | Robert Randall Chief Financial Officer, Corporate Secretary |
| Business Overview |
| Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property. |
| Financial Overview |
| For the three months ended 31 January 2024, Sona Nanotech Inc revenues was not reported. Net loss increased 91% to C$759K. Higher net loss reflects Research and development costs increase from C$12K to C$92K (expense), Salaries and benefits increase of 30% to C$244K (expense), Recovery ofproject expenses decrease from C$39K (income) to C$0K. Basic Earnings per Share excluding Extraordinary Items remained flat at -C$0.01. |
| Employees: | 8 as of Oct 31, 2021 |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $37.10M as of Jan 31, 2024 |
| Annual revenue (TTM): | $0.00M as of Jan 31, 2024 |
| EBITDA (TTM): | -$2.54M as of Jan 31, 2024 |
| Net annual income (TTM): | -$2.86M as of Jan 31, 2024 |
| Free cash flow (TTM): | -$1.87M as of Jan 31, 2024 |
| Net Debt Last Fiscal Year: | $0.40M as of Jan 31, 2024 |
| Shares outstanding: | 99,145,361 as of Jan 31, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
